Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 97.86
Day High 99.99
Open:99.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports+

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

The Global Breast Cancer Drugs Market is expected to grow from USD 15,188.90 Million in 2019 to USD 25,364.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%
- PR Newswire - PRF - Thu Jul 2, 10:10AM CDT
PR Newswire - PRF - CMTX
Thu Jul 2, 10:10AM CDT
, /PRNewswire/ --Read the full report: The Global Breast Cancer Drugs Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%.Market Segmentation & Coverage:This research report categorizes the Breast Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:On the basis of Type, the Breast Cancer Drugs Market is studied across Anti-metabolites, Aromatase inhibitor, CDK 4/6 inhibitor, HER2 inhibitor, Hormonal receptor, and Mitotic inhibitor. On the basis of Geography, the Breast Cancer Drugs Market is studied across Americas, , and , & . The Americas region is studied across , , , , and . The region is studied across , , , , , , , , and . The , & region is studied across , , , , , , , , , , and . Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Drugs Market including AbbVie, Inc., Astellas Pharma Inc., AstraZeneca, BioNumerik Pharmaceuticals Inc., Celgene Corporation, Celldex Therapeutics, F. Hoffman-La Roche Pvt. Ltd, Genentech, Inc., Genzyme Corporation, Janssen Global Services LLC, MacroGenics Inc., Merck & Co Inc., Novartis AG, Onyx Pharmaceuticals, Inc., and Pfizer Inc.. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments1. What is the market size and forecast of the Global Breast Cancer Drugs Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Drugs Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Drugs Market?4. What is the competitive strategic window for opportunities in the Global Breast Cancer Drugs Market?5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Drugs Market?6. What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Drugs Market?Read the full report: About ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001
Global Bruton's Tyrosine Kinase Inhibitors Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19
- PR Newswire - PRF - Fri Jun 26, 3:30PM CDT
PR Newswire - PRF - CMTX
Fri Jun 26, 3:30PM CDT
, /PRNewswire/ -- The report has been added to offering.
Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
- PR Newswire - PRF - Fri Jun 26, 12:15AM CDT
PR Newswire - PRF - CMTX
Fri Jun 26, 12:15AM CDT
, /PRNewswire/ -- Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin® therapy for patients with neovascular (wet) age-related macular degeneration (nAMD).
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 89.60 +10.36% increase
on 06/03/20
Period Open:91.04
Price movement based on the high, low and last over the given period.
99.99 -1.11% decrease
on 07/02/20
+7.84 (+8.61%) increase
since 06/02/20
3-Month 72.55 +36.29% increase
on 04/03/20
Period Open:75.13
Price movement based on the high, low and last over the given period.
99.99 -1.11% decrease
on 07/02/20
+23.75 (+31.61%) increase
since 04/02/20
52-Week 62.55 +58.08% increase
on 03/23/20
Period Open:74.23
Price movement based on the high, low and last over the given period.
99.99 -1.11% decrease
on 07/02/20
+24.65 (+33.21%) increase
since 07/02/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies